NCT05161390View on ClinicalTrials.gov

Study of LM-302 in Patients With Advance Solid Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

153

Participants

Timeline

Start Date

November 26, 2021

Primary Completion Date

January 10, 2025

Study Completion Date

January 10, 2025

Conditions

Advanced Solid Tumor

Interventions

DRUG

LM-302 Injection

LM-302 Injection with dose escalation stage of different dose levels, as well as dose expansion stage with recommended dose level from dose escalation stage.

Trial Locations (1)

Unknown

Shanghai East Hospital, Shanghai

All Listed Sponsors

lead

LaNova Medicines Zhejiang Co., Ltd.

INDUSTRY

NCT05161390 - Study of LM-302 in Patients With Advance Solid Tumors | Biotech Hunter | Biotech Hunter